Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.96 USD
Change Today +0.17 / 3.55%
Volume 883.1K
ONVO On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 8:04 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

organovo holdings inc (ONVO) Snapshot

Open
$4.74
Previous Close
$4.79
Day High
$5.00
Day Low
$4.70
52 Week High
07/7/14 - $9.25
52 Week Low
03/30/15 - $3.29
Market Cap
404.2M
Average Volume 10 Days
749.3K
EPS TTM
$-0.37
Shares Outstanding
81.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORGANOVO HOLDINGS INC (ONVO)

organovo holdings inc (ONVO) Related Bloomberg News

View More Bloomberg News

organovo holdings inc (ONVO) Related Businessweek News

View More BusinessWeek News

organovo holdings inc (ONVO) Details

Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; Janssen Pharmaceuticals; and L’Oreal. The company was founded in 2007 and is headquartered in San Diego, California.

67 Employees
Last Reported Date: 02/6/15
Founded in 2007

organovo holdings inc (ONVO) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $362.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $289.1K
Chief Strategy Officer
Total Annual Compensation: $289.8K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $289.1K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $268.5K
Compensation as of Fiscal Year 2014.

organovo holdings inc (ONVO) Key Developments

Organovo Holdings, Inc. Reports Revenue Guidance for the Fourth Quarter and Fiscal Year Ended March 31, 2015

Organovo Holdings, Inc. reported revenue guidance for the fourth quarter and fiscal year ended March 31, 2015. Based on preliminary financial information for the first quarter of 2015, the company estimates total net revenues of approximately $268,000. Based on preliminary financial information for the fiscal year-ended March 31, 2015, the company estimates total net revenues of approximately $571,000.

Organovo Holdings Appoints Kirk Malloy as New Class I Director

Organovo Holdings, Inc. announced the appointment of Kirk Malloy, Ph.D. as a new Class I director. At the time of his initial appointment, Dr. Malloy was not appointed to any of the board's standing Committees. On March 16, 2015, Dr. Malloy was appointed as a member of each of the Board's Compensation Committee, Nominating and Corporate Governance Committee and Science and Technology Committee.

Organovo Holdings, Inc. - Special Call

To provide a business update, including an update on the commercial launch of the company's exVive3D Liver, Bioprinted Human Tissue and a discussion of the commercialization milestones for the company's 3D bioprinted kidney tissue

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONVO:US $4.96 USD +0.17

ONVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $4.64 USD -0.07
Cytori Therapeutics Inc $0.73 USD +0.0427
Fibrocell Science Inc $4.08 USD +0.09
Ocata Therapeutics Inc $6.36 USD -0.14
Osiris Therapeutics Inc $18.68 USD -0.01
View Industry Companies
 

Industry Analysis

ONVO

Industry Average

Valuation ONVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 920.2x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 800.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORGANOVO HOLDINGS INC, please visit www.organovo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.